全球 DLL3 標靶治療市場：市場機會、已通過核准療法銷售、定價、專有開發平台和臨床試驗洞察（2030 年）

「DLL3標靶療法全球市場—市場機會、已通過核准療法銷售、定價、專有開發平台和臨床試驗（2030年）」報告的主要發現和亮點：

• 全球DLL3標靶治療市場機會 > 到2030年超過20億美元
• 對當前趨勢和未來市場機會的評估
• 美國正在推動市場銷售，而中國在 DLL3 臨床試驗趨勢方面處於領先地位。
• DLL3標靶治療臨床試驗的最新進展：超過50種治療方法
• 按公司、適應症和臨床試驗階段分類的DLL3標靶治療的全球臨床實驗狀況
• 對用於開發標靶治療的專有平台進行分析
• 競爭格局

DLL3標靶治療的必要性及本報告的意義

DLL3標靶治療是精準醫療和標靶癌症治療領域發展最快的方向之一。 DLL3（Delta樣配體3）是Notch訊號路徑的抑制性配體，在小細胞肺癌（SCLC）和許多其他高度侵襲性的神經內分泌腫瘤中大量表達，但在正常成人組織中則不表達。由於DLL3具有腫瘤選擇性，其在腫瘤中的表現圖譜使其成為新型抗癌藥物研發的理想標靶。與針對所有快速生長細胞的標準療法不同，DLL3標靶治療能夠特異性識別癌細胞，從而提高治療的精準度並減少脫靶效應的副作用。隨著對腫瘤生物學認知的不斷深入，DLL3已成為一種成熟的藥物靶點，可用於T細胞銜接器、抗體藥物複合體物（ADC）、細胞療法、放射性藥物以及許多其他新型標靶治療。

自Imdelltra（tarlatamab）獲準以來，DLL3標靶治療市場取得了顯著進展。 Imdelltra是目前唯一認證核可藥。該療法的監管批准證實了其臨床療效，並刺激了全球對下一代療法的投資。

本報告整體情況分析了DLL3標靶治療，涵蓋科學進展、作用機制、技術平台、市場促進因素、臨床開發、競爭分析、區域趨勢和商業化潛力。本報告將幫助製藥公司、生技公司、投資者、科學家和醫療保健相關人員了解這個充滿活力的市場環境，並探索該領域的合作和授權機會。

本報告中包含對臨床試驗的深入分析

臨床試驗的進展仍是影響DLL3標靶治療市場未來發展的重要因素。目前，Imdelltra是唯一可用的DLL3標靶治療藥物，但還有許多其他療法正在研發中，均處於臨床前和臨床開發階段，針對多種類型的癌症。本報告全面分析了所有正在進行的DLL3標靶治療治療臨床臨床實驗，這些療法針對小細胞肺癌、大細胞神經內分泌癌、神經內分泌前列腺癌、胃腸道和胰腺神經內分泌腫瘤、膠質瘤以及其他表達DLL3的癌症。除了分析處於所有開發階段（包括研究、臨床前、I期、I/II期和II期）的臨床項目外，本報告還涵蓋了多種療法，包括雙特異性抗體、抗體藥物複合體（ADC）、細胞療法和抗體放射性核素偶聯物。

此外，本報告按公司、適應症、患者群體、地區、研發階段和監管環境，深入分析了臨床試驗趨勢，並在每個章節中重點介紹了特定的藥物類別。除了單一藥物治療外，人們越來越關注聯合治療，即將DLL3標靶治療與化療、免疫查核點抑制劑、標靶治療療法或其他在臨床實驗藥物合併使用，以提高療效並拓展治療選擇。豐富的臨床數據有助於了解研發管線的進展和新興治療領域，並對最具潛力的臨床候選藥物在整體情況DLL3標靶治療的競爭地位競爭考察。

專注於DLL3標靶治療研發的領先公司

在越來越多的跨國製藥公司、生技公司和學術機構積極探索針對錶達DLL3的癌症的新療法的推動下，DLL3標靶治療領域持續發展。在臨床證實DLL3的治療價值後，安進公司憑藉Imdelltra的商業化，在該競爭激烈的領域確立了主導地位。除安進公司外，許多公司正採用多種方法開發基於DLL3的產品，包括抗體藥物複合體（ADC）、雙特異性和三特異性抗體、放射性藥物和細胞療法。該領域的主要參與者包括再鼎醫藥、勃林格殷格翰、Phanes Therapeutics和其他生物技術公司。

本報告概述了參與DLL3療法研發的主要公司，分析了它們的研發活動、技術平台、臨床管線和策略。大型製藥公司和創新生物技術公司擴大涉足基於DLL3的療法研發，顯示該領域正受到越來越多的科學界和商業性的關注。預計投資的增加和管線的持續開發將進一步加劇競爭。

技術平台、合作夥伴關係和協議

技術創新是DLL3標靶治療市場的關鍵特徵，研發人員正利用各種專有平台來提高其在研療法中的療效、選擇性和安全性。目前正在研發的技術包括雙特異性T細胞銜接器、三重抗體、抗體藥物複合體（ADC）、基因修飾細胞療法、抗體放射性核種偶聯物和光免疫療法平台。安進公司的BiTE®平台技術已透過Imdelltra證明了免疫細胞銜接的臨床價值，許多其他研發人員也在致力於開發各自的ADC技術、新一代抗體工程平台、放射性核種遞送系統和細胞療法，以增強DLL3標靶療法的治療價值。

合作研究和策略夥伴關係匯聚了藥物發現、生產和臨床研究領域的專家，推動技術創新。例如，再鼎醫藥與安進公司合作，共同研究佐西妥昔單抗（zoci）與伊維菌素（Imdelltra）聯合治療治療晚期小細胞肺癌。此外，再鼎醫藥也與勃林格殷格翰公司合作，研究一種靶向DLL3的雙靶點策略，即將佐西妥昔單抗與DLL3/CD3 T細胞活化劑奧布利西米（oblixtamig）聯合使用，用於治療小細胞肺癌和神經內分泌腫瘤。這些合作凸顯了整合研發策略在未來DLL3標靶治療開發中的重要性。

一份概述 DLL3標靶治療未來方向的報告。

DLL3標靶治療的未來發展將持續受到創新、多元化應用領域以及精準腫瘤治療工具開發的驅動。多特異性抗體、抗體藥物偶聯物（ADC）、放射性藥物和細胞療法正在研發中，旨在提高靶向特異性、激活免疫系統、改善藥物藥物動力學並克服抗藥性。基於生物標記的患者篩選和個人化治療方案可能有助於最佳化DLL3標靶療法的療效。

隨著更多藥物進入臨床試驗並獲得監管部門批准，DLL3標靶治療市場的商業性前景預計將持續擴大。 Imdelltra的成功——預計到2025年將為公司帶來超過6億美元的收入——證明了DLL3作為治療標靶的巨大潛力，並推動了該領域的進一步發展。臨床實踐、監管、技術以及製藥和生物技術公司之間合作的進步，都將有助於市場擴張，並在腫瘤治療領域創造新的機會。

目錄

第1章：DLL3標靶治療概述

• 概述
• DLL3標靶治療的歷史與發展
• DLL3 作為診斷和預後標記的作用。

第2章：DLL3標靶化方法、機制與商業性面

• 抗體藥物複合體
• 抗體
• 細胞療法
• 抗體放射性核種複合物
• 抗體-光吸收劑/光敏劑複合物

第3章：DLL3標靶治療的獨特平台

第4章：DLL3標靶治療市場及臨床趨勢分析

• 目前市場展望及治療藥物銷售洞察（2024-2026）
• 未來市場機會與銷售預測（2026-2030 年）

第5章：伊達曲唑－首個獲準的標靶DLL3的標靶藥物

• 臨床概述和專利信息
• 定價和劑量分析
• 銷售分析（2024-2026）

第6章：DLL3標靶治療的全球臨床開發與市場趨勢（依適應症區分）

• 小細胞肺癌
• 大細胞神經內分泌癌
• 膠質瘤
• 神經內分泌性前列腺癌
• 胃腸道胰臟神經內分泌腫瘤

第7章：DLL3標靶治療及區域市場趨勢調查

• 美國
• 中國
• 歐洲聯盟
• 加拿大
• 英國
• 澳洲

第8章 DLL3標靶治療全球臨床試驗概述

• 步步
• 公司
• 透過監管指定
• 適應症
• 按地區

第9章 按公司、適應症和階段分類的DLL3標靶治療的全球臨床試驗

• 研究
• 臨床前
• 階段0
• 第一階段
• 第一/二期
• 第二階段
• 第三階段

第10章：市售 DLL3標靶藥物的臨床試驗（按公司、適應症和階段分類）

第11章 DLL3標靶治療市場動態

• 有利的市場環境和臨床開發參數
• 挑戰與限制

第12章：參與DLL3標靶治療研發的主要公司

• Abdera Therapeutics
• Allogene Therapeutics
• Amgen
• Boehringer Ingelheim
• Chugai Pharmaceutical
• Gensun Biopharma
• Harpoon Therapeutics
• ImaginAb Inc
• Legend Biotech
• Molecular Partners
• Phanes Therapeutics
• Qilu Pharmaceutical
• Shanghai Affinity Biopharmaceutical
• ZAI Lab

Global DLL3 Targeted Therapies Market Opportunity, Approved Therapy Sales, Pricing, Proprietary Development Platforms & Clinical Trials Insight 2030 Report Findings & Highlights:

• Global DLL3 Targeted Therapies Market Opportunity > USD 2 Billion By 2030
• Current Trends & Future Opportunity Assessment
• US Will Dominate Market Sales & China Will Lead DLL3 Clinical Trials Landscape
• Insight On DLL3 Targeted Therapies In Clinical Trials: > 50 Therapies
• Global DLL3 Targeted Therapies In Clinical Trials By Company, Indication & Phase
• Insight On DLL3 Targeted Therapies Development Proprietary Platforms
• Competitive Landscape

Need For DLL3 Targeted Therapies & Why This Report?

DLL3 targeted therapies constitute one of the most rapidly growing categories in precision medicine and targeted cancer treatments. DLL3 (delta-like ligand 3), an inhibitory ligand of Notch signaling, is expressed abundantly in SCLC and in a number of other highly aggressive neuroendocrine cancers but not in adult normal tissues. The expression profile of DLL3 in tumors has made this molecule an interesting target for development of novel anti-cancer agents due to its tumor selectivity. In contrast to standard therapies that target all rapidly proliferating cells, DLL3 targeted therapies can specifically identify cancer cells, which provides better precision of treatment and reduces side effects associated with off target activity. In the context of growing knowledge about tumor biology, DLL3 has become a validated drug target that is able to be used for T-cell engagers, ADCs, cell therapies, radiopharmaceuticals, and many other novel targeted treatments.

There have been tremendous developments in the DLL3 targeted therapy market since the approval of Imdelltra (tarlatamab), which became the only approved drug targeting DLL3 to date. Regulatory approval of this approach has established its clinical viability and has spurred global investments into next-generation treatment modalities.

This report offers an exhaustive analysis of the DLL3 targeted therapy landscape through its scientific progress, mechanism of action, technology platforms, market factors, clinical development, competitive analysis, regional trends, and commercialization potential. It will help drug makers, biotech companies, investors, scientists, and healthcare players understand the dynamic market environment and seek collaboration and licensing opportunities in the sector.

Clinical Trials Insight Included In Report

The development of clinical trials continues to be the main force influencing the future of the DLL3 targeted therapy market. Even though Imdelltra is the only available therapy targeting DLL3, there are many other investigational therapies in the pipeline, which are under various phases of preclinical and clinical development for various types of cancer. The report covers a comprehensive analysis of all the ongoing clinical trials of DLL3 targeted therapies for small cell lung cancer, large cell neuroendocrine carcinoma, neuroendocrine prostate cancer, gastroenteropancreatic neuroendocrine tumors, glioma, and other types of cancers expressing DLL3. The report covers the analysis of clinical programs in all development phases such as Research, Pre-clinical, Phase I, Phase I/II, and Phase II along with various treatment modalities involving bispecific antibodies, antibody drug conjugate, cell therapy, antibody radionuclide conjugate and many others.

In addition, the report provides insights into clinical trial trends by company, indication, patient population, geographic region, development phase and regulatory status, highlighting any special drug designations in the respective section. Besides the monotherapy approach, there is an ever growing focus on combination regimens combining DLL3 targeted therapies with chemotherapy, immune checkpoint inhibitors, targeted agents or other investigational compounds to improve efficacy and broaden therapeutic options. Rich clinical details allow to comprehend the advancement stage of the pipeline and emerging therapeutic areas, and to gain a competitive insight into the competitive positioning of the most promising clinical candidates throughout the DLL3 targeted therapy landscape.

Major Companies Active In R&D Of DLL3 Targeted Therapies

The field of DLL3 targeted therapies is evolving with increasing numbers of multinational pharma companies, biotech firms, and academic institutions actively researching novel therapies in DLL3 expressing cancers. Amgen's lead in this competitive field is established with the commercial launch of Imdelltra following the validation of DLL3 as a therapeutically relevant target in the clinic. In addition to Amgen, there are many companies working on development of DLL3 based products using various approaches such as antibody-drug conjugates, bispecific and trispecific antibodies, radiopharmaceuticals and cell therapies. The industry's key players include Zai Lab, Boehringer Ingelheim, Phanes Therapeutics, and other biotech firms.

This report provides a review of leading organizations involved in DLL3 therapy development and considers their research activities, technology platforms, clinical pipeline and strategy. The increasing involvement of large pharmaceutical companies and innovative biotech firms in the development of DLL3 based therapies testifies to the growing scientific and commercial interest in the segment. Increasing investments and continued development of the pipeline are likely to make competition even stronger.

Technology Platforms, Collaborations & Agreements

Technological innovation is an important feature of the DLL3 targeted therapy market with developers employing different proprietary platforms in their quest to improve the therapeutic efficacy, selectivity, and safety of the therapies being developed. Currently under development are bispecific T-cell engagers, trispecific antibodies, antibody-drug conjugates, engineered cell therapies, antibody radionuclide conjugates, and photoimmunotherapy platforms. BiTE(R) platform technology from Amgen has proven the clinical value of immune cell engagement with Imdelltra while many other developers are working on their proprietary ADC technology, next-generation antibody engineering platforms, radionuclide delivery systems, and cell therapies for enhancing the therapeutic value of the therapies that target DLL3.

Collaborations and strategic alliances are driving technological innovations by pooling together different experts in drug development, manufacturing, and clinical research. An example of such an alliance is the one that was struck between Zai Lab and Amgen to investigate the combination of zocilurtatug pelitecan (zoci) and Imdelltra for the treatment of extensive-stage small cell lung cancer. In addition to this, Zai Lab has partnered with Boehringer Ingelheim to study a dual DLL3-targeting strategy combining zoci and obrixtamig, a DLL3/CD3 T-cell engager, for the treatment of small cell lung cancer and neuroendocrine carcinomas. These partnerships underscore the significance of integrated developmental strategies for the future development of DLL3 therapies.

Report Indicating Future Direction Of DLL3 Targeted Therapies

Future developments in DLL3-targeted therapies will continue to revolve around innovation, diverse application areas, and the development of precise oncology tools. Multispecific antibodies, ADCs, radiopharmaceuticals, and cell-based therapies are being developed to enhance the specificity of targeting, immune system activation, pharmacokinetics of therapeutic substances, and overcoming drug resistance. Patient selection using biomarkers and individualized therapeutic approaches may help to optimize the results of DLL3 based therapies.

Commercial prospects of the DLL3 targeted therapy market will continue to grow as more agents advance into clinical trials and receive regulatory approval. Success of Imdelltra, which earned the company an revenue of more than US$ 600 Million in 2025, serves as basis of potential of DLL3 as a therapeutic target and encourages further development in this field. The development in clinical practice, regulation, technology, and partnerships between pharma and biotech companies will help expand the market and provide new opportunities within oncology indications.

Table of Contents

1. Introduction To DLL3 Targeted Therapies

• 1.1 Overview
• 1.2 History & Evolution Of DLL3 Targeted Therapies
• 1.3 Role Of DLL3 As Diagnostic & Prognostic Markers

2. DLL3 Targeting Approaches, Mechanism & Commercial Aspects

• 2.1 Antibody Drug Conjugates
• 2.2 Antibodies
• 2.3 Cell Therapies
• 2.4 Antibody Radionuclide Conjugates
• 2.5 Antibody Photoabsorber/Photosensitizer Conjugate

3. DLL3 Targeted Therapies Proprietary Platforms

4. DLL3 Targeted Therapies Market & Clinical Trends Insights

• 4.1 Current Market Outlook & Therapy Sales Insight ( 2024 - 2026)
• 4.2 Future Market Opportunity & Sales Forecast (2026 -2030)

5. Imdelltra - 1st Approved DLL3 Targeted Drug

• 5.1 Clinical Overview & Patent Insight
• 5.2 Pricing & Dosage Analysis
• 5.3 Sales Analysis (2024 - 2026)

6. Global DLL3 Targeted Therapies Clinical Development & Market Insight By Indication

• 6.1 Small Cell Lung Cancer
• 6.2 Large-cell neuroendocrine carcinoma
• 6.3 Glioma
• 6.4 Neuroendocrine Prostate Cancer
• 6.5 Gastroenteropancreatic Neuroendocrine Tumors

7. DLL3 Targeted Therapies Research & Market Trends by Region

• 7.1 US
• 7.2 China
• 7.3 EU
• 7.4 Canada
• 7.5 UK
• 7.6 Australia

8. Global DLL3 Targeted Therapies Clinical Trials Overview

• 8.1 By Phase
• 8.2 By Company
• 8.3 By Regulatory Designation
• 8.4 By Indication
• 8.5 By Location

9. Global DLL3 Targeted Therapies Clinical Trials By Company, Indication & Phase

• 9.1 Research
• 9.2 Preclinical
• 9.3 Phase-0
• 9.4 Phase-I
• 9.5 Phase-I/II
• 9.6 Phase-II
• 9.7 Phase-III

10. Marketed DLL3 Targeted Drugs Clinical Trials By Company, Indication & Phase

11. DLL3 Targeted Therapies Market Dynamics

• 11.1 Favorable Market & Clinical Development Parameters
• 11.2 Challenges & Restraints

12. Key Companies Involved In Research & Development Of DLL3 Targeted Therapies

• 12.1 Abdera Therapeutics
• 12.2 Allogene Therapeutics
• 12.3 Amgen
• 12.4 Boehringer Ingelheim
• 12.5 Chugai Pharmaceutical
• 12.6 Gensun Biopharma
• 12.7 Harpoon Therapeutics
• 12.8 ImaginAb Inc
• 12.9 Legend Biotech
• 12.10 Molecular Partners
• 12.11 Phanes Therapeutics
• 12.12 Qilu Pharmaceutical
• 12.13 Shanghai Affinity Biopharmaceutical
• 12.14 ZAI Lab

List of Figures

• Figure 2-1: Antibody Drug Conjugates - Mechanism Of Action
• Figure 2-2: BiTE - Amgen
• Figure 2-3: HPN328 - Structure
• Figure 2-4: Rova-IR700 - Mechanism
• Figure 3-1: T-Charge Platform - Features
• Figure 3-2: BiTE(R) Antibody Construct
• Figure 3-3: TMALIN - ADC Advantages
• Figure 3-4: TMALIN - ADC Structure
• Figure 3-5: TriTAC - T-Cell Engagers Structure
• Figure 3-6: TriTAC - Advantages
• Figure 3-7: PACbody(TM) Platform
• Figure 3-8: ATACCbody(TM) Platform
• Figure 3-9: SPECpair(TM) Platform
• Figure 3-10: ROVEr Platform - Process
• Figure 3-11: RPT - Advantages
• Figure 3-12: Dual-Ig Technology - Antibody Structure & Mechanism
• Figure 3-13: AlloCAR T - Process
• Figure 3-14: AlloCAR T - Features
• Figure 3-15: Alluminox(TM) Platform - Drug Structure
• Figure 3-16: Rakuten Medical - Photoimmunotherapy Process
• Figure 4-1: Global - DLL3 Targeted Therapies Sales (US$ Million), 2024 - 2026
• Figure 4-2: Global - DLL3 Targeted Therapies Sales By Region (US$ Million), Q1'2026
• Figure 4-3: Global - DLL3 Targeted Therapies Sales By Region (US$ Million), 2025
• Figure 4-4: Global - DLL3 Targeted Therapies Sales By Quarter (US$ Million), 2025
• Figure 4-5: Global - DLL3 Targeted Therapies Sales (US$ Billion), 2026 - 2030
• Figure 5-1: Imdelltra - Approval By Region & Year
• Figure 5-2: US & EU - Imdelltra Price Per Supply (US$), July'2026
• Figure 5-3: Global - Imdelltra Sales (US$ Million), 2024 - 2026
• Figure 5-4: Imdelltra - Global Sales By Region (US$ Million), Q1'2026
• Figure 5-5: Imdelltra - Global Sales By Region (US$ Million), 2025
• Figure 5-6: Imdelltra - Global Sales By Quarter (US$ Million), 2025
• Figure 5-7: Imdelltra - US Sales (US$ Million), 2024 - 2026
• Figure 5-8: Imdelltra - US Sales By Quarter (US$ Million), 2025
• Figure 5-9: Imdelltra - ROW Sales (US$ Million), 2025 & 2026
• Figure 5-10: Imdelltra - ROW Sales By Quarter (US$ Million), 2025
• Figure 6-1: DeLLphi-301 Phase II (NCT05060016) Study - Initiation & Completion Year
• Figure 6-2: DeLLphi-304 Phase III (NCT05740566) Study - Initiation & Completion Year
• Figure 6-3: DAREON(R)-8 Phase I (NCT06077500) Study - Initiation & Completion Year
• Figure 6-4: DAREON(R)-9 Phase I (NCT05990738) Study - Initiation & Completion Year
• Figure 6-5: DAREON(R)-5 Phase II (NCT05882058) Study - Initiation & Completion Year
• Figure 6-6: DAREON(R)-LUNG-1 Phase III (NCT07472517) Study - Initiation & Completion Year
• Figure 6-7: SKYBRIDGE Phase I/II (NCT05652686) Study - Initiation & Completion Year
• Figure 6-8: HPN328-4001 Phase I/II (NCT04471727) Study - Initiation & Completion Year
• Figure 6-9: LB2102-1001 Phase I (NCT05680922) Study - Initiation & Completion Year
• Figure 6-10: 2024-519111-34-00 Phase I (NCT07006727) Study - Initiation & Completion Year
• Figure 6-11: RABBIT Phase I/II (NCT06814496) Study - Initiation & Completion Year
• Figure 6-12: 2024-519111-34-00 Phase I (NCT05916313) Study - Initiation & Completion Year
• Figure 6-13: IMI-IRB-25003 Phase I (NCT07180927) Study - Initiation & Completion Year
• Figure 6-14: DeLLight Phase II (NCT06893783) Study - Initiation & Completion Year
• Figure 6-15: PCCTC #C24-347 Phase II (NCT07180927) Study - Initiation & Completion Year
• Figure 8-1: Global - Number Of DLL3 Targeted Therapies In Clinical Trials By Phase, 2026
• Figure 8-2: Global - Number Of DLL3 Targeted Therapies In Clinical Trials By Company, 2026
• Figure 8-3: Global - Number Of DLL3 Targeted Therapies In Clinical Trials By Regulatory Designation, 2026
• Figure 8-4: Global - DLL3 Targeted Therapies In Clinical Trials By Indication (Number), 2026
• Figure 8-5: Global - DLL3 Targeted Therapies In Clinical Trials By Location (Number), 2026
• Figure 11-1: DLL3 Targeted Therapies - Market Drivers & Opportunities
• Figure 11-2: DLL3 Targeted Therapies - Market Challenges & Restraints

List of Tables

• Table 5-1: Imdelltra - Recommended Dosage and Schedule
• Table 5-2: Imdelltra - Recommended Concomitant Medications for Administration for Cycle 1
• Table 5-3: Imdelltra - Recommendations for Restarting Therapy After Dosage Delay
• Table 7-1: US - FDA Designated DLL3 Targeted Therapies